Dermatol. praxi. 2011;5(2):69-71

Practical management of atopic dermatitis

MUDr.Anna Jiráková, MUDr.Jana Bernardová, prof.MUDr.Jana Hercogová, CSc.
Dermatovenerologická klinika 2. LF UK a FN Na Bulovce, Praha

Atopic dermatitis is a multifactorial non-infectious inflammatory skin disease of the chronic and relapsing character. It is very common

disease, its incidence is still growing. Most commonly it affects young children. Prevalence of atopic dermatitis in adults is 2–10 % and

in children 15–30 %. Relevance of this disease depends on the extent of its symptoms, frequency of the exacerbations, complications

but mostly on the significant impact on the quality of life. It is of a great importance that atopic dermatitis influences quality of life not

only of the patient himself but also his family. The aims of the therapy of atopic dermatitis are: reduction of the major symptoms of the

disease, prevention against exacerbations of the disease and long-term protection and care of the skin. The detailed education of the

patient and his family is necessary. The most significant topical modalities used in the treatment of atopic dermatitis are emollients, in

acute exacerbations topical corticosteroids and topical immunomodulators. Those are recommended for long-term therapy in so-called

“proactive” regime.

Keywords: atopic dermatitis, pruritus, corticosteroids, topical immunomodulators

Published: June 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jiráková A, Bernardová J, Hercogová J. Practical management of atopic dermatitis. Dermatol. praxi. 2011;5(2):69-71.
Download citation

References

  1. Kang K, Polster AM, Nedorost ST, et al. Atopic dermatitis. In: Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. 1st ed, vol. 1. Elsevier 2003: 149-174.
  2. Lam J, Friedlander SF. Atopic Dermatitis: A recent advances in the field. Paediatr Health, 2008; 2(6): 733-747. Go to original source...
  3. Wolff K, Johnson RA. Fitzpatrick's colour atlas and synopsis of clinical dermatology. 5th Ed. McGraw-Hill 2005; 33-38.
  4. Williams H, Flor C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol, 2006; 118: 209-213. Go to original source... Go to PubMed...
  5. Simpson EL. Atopic dermatitis: a review of topical treatment options. Current Medical Research and Opinions, 2010; 26(3): 633-640. Go to original source... Go to PubMed...
  6. Jirákova A, Slavíková Š, Vojáčková N, Göpfertová D, Hercogová J. Vliv atopického ekzému dítěte na členy jeho rodiny - česká validace dotazníku. Čes-slov Derm, 2010; 85(6): 318-324.
  7. Benáková N. Atopická dermatitida v roce 2009. Čes-slov Derm, 2009; 84(2): 65-86.
  8. Jiráková A, Slavíková Š, Vojáčková N, Hercogová J. Atopická dermatitida. Postgraduální medicina, 2010; 12(4): 409-418.
  9. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract, 2006; 60(8): 984-992. Go to original source... Go to PubMed...
  10. Möhrenschlager M, Darsow U, Schnopp C, et al. Atopic eczema: What is new? JEADV, 2006; 20(5): 503-511. Go to original source... Go to PubMed...
  11. Hercogová J. Léčebné možnosti u atopické dermatitidy. Komentář. Medicína po promoci, 2007; 8(3): 44-45.
  12. Grimalt R, Mengeaud V, Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology, 2007; 214(1): 61-67. Go to original source... Go to PubMed...
  13. Simpson E, et al. A pilot study of emollients therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol, 2010; 63(4): 587-593. Go to original source... Go to PubMed...
  14. Sugarman J, Parish L. Efficacy of a lipid-based, barier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol, 2009; 8(12): 1106-1111. Go to PubMed...
  15. Patrizi A, Raone B, Neri I. MAS063DP cream. Expert Opin Pharmacother, 2009; 10(7): 1223-1230. Go to original source... Go to PubMed...
  16. Hachem JP, Roelandt T, Schürer N, et al. Acute acidification of stratum corneum membrane domains using polyhydroxyl acids improves processing and inhibits degradation of corneodesmosomes. J Invest Dermatol, 2010; 130(2): 500-510. Go to original source... Go to PubMed...
  17. Hercogová J. Topical anti-itch therapy. Dermatol Therapy, 2005; 18(4): 341-343. Go to original source... Go to PubMed...
  18. Warner MR, Camisa Ch. Topical Corticosteroids. In: Wolverton S. Comprehensive Dermatologic Drug therapy. 2nd ed. Elsevier, 2007: 700-732.
  19. Carruthers JA, et al. Observations on the systemic effect of topical clobetasol propionate. Br Med J, 1975; 4: 203-204. Go to original source... Go to PubMed...
  20. Čapková Š. Možnosti léčby atopické dermatitidy v roce 2008. Farmakoterapie 2008; Suppl. 3: 22-31.
  21. Thestrup-Pedersen K. Tacrolimus treatment of atopic eczema/dermatitis syndrome. Curr Opin Allergy Clin Immunol, 2003; 3(5): 359-362. Go to original source... Go to PubMed...
  22. Gupta AK, Chow M. Pimecrolimus: A review. JEADV, 2003; 17(5): 493-503. Go to original source... Go to PubMed...
  23. Paller A, Brinkmann W, Rico J, et al. A prospective pediatric longitudinal evaluation to assess the long-term safety of tacrolimus ointment for the atopic dermatitis. J Am Acad Dermatol, 2007; 56(Suppl 2): 2AB3. Go to original source...
  24. Misery L. Therapeutic perspectives in atopic dermatitis. Clin Rev Allergy Immunol. 2010. [Epub ahead of print]. Go to original source...
  25. www.emea.europa.eu/humandocs/PDFs/EPAR/protopic/ emea-combined-h374en.pdf.




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.